Drug profile · INN
pazopanib
PAZOPANIB ADVZ
pazopanib (PAZOPANIB ADVZ) is a vascular endothelial growth factor receptor inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01XE11
Patents linked 0
Pipeline programs 7
News articles 0
Drug details — pazopanib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
pazopanib (PAZOPANIB ADVZ) is a vascular endothelial growth factor receptor inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN pazopanib
Brand PAZOPANIB ADVZ
Mechanism Vascular endothelial growth factor receptor inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE11
Originator Novartis Pharmaceuticals
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pazopanib?
pazopanib (PAZOPANIB ADVZ) is a vascular endothelial growth factor receptor inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for pazopanib?
PAZOPANIB ADVZ is a marketed brand name for pazopanib. Check FDA Drugs@FDA for the current US label holder and prescribing information.